Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA

Clinical Cancer Research

Volumn 10, Issue 15, 2004, Pages 4983-4990

  Nosrati, Mehdi ^a   Li, Shang ^c   Bagheri, Sepideh ^a   Ginzinger, David ^b   Blackburn, Elizabeth H ^c   Debs, Robert J ^d   Kashani Sabet, Mohammed ^a,b  

^a Cutaneous Oncology Program   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d California Pacific Medical Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HAMMERHEAD RIBOZYME; LIPOSOME; MOUSE TELOMERASE RNA; PLASMID VECTOR; RECOMBINANT ENZYME; RIBOZYME; RNA; TELOMERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B16 F10 MURINE MELANOMA; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; GENE MUTATION; IN VIVO STUDY; METASTASIS; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; VIRUS GENOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CATIONS; CELL LINE, TUMOR; CLONING, MOLECULAR; DISEASE PROGRESSION; DNA; FEMALE; LIPOSOMES; LUNG; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MODELS, GENETIC; MUTATION; NEOPLASM METASTASIS; NEOPLASMS; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, CATALYTIC; TELOMERASE; TELOMERE; TIME FACTORS;

EID: 4143124424     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0134     Document Type: Article

References (38)

1. Blackburn EH. Telomere states and cell fates. Nature 2000;408:53-6.
2. Zakian VA. Telomeres: beginning to understand the end. Science 1995;270:1601-17.
3. Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992;11:1921-9.
4. Greider CW, Blackburn EH. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 1987;51:887-98.
5. Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989;337:331-7.
6. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8.
7. Stewart SA, Hahn WC, O'Connor BF, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 2002;99:12606-11.
8. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
9. Hiyama E, Hiyama K. Clinical utility of telomerase in cancer. Oncogene 2002;21:643-9.
10. Zhang W, Piatyszek MA, Kobayashi T, et al. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res 1996;2:799-803.
11. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell 2002;2:257-65.
12. Herbert B, Pitts AE, Baker SI, et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 1999;96:14276-81.
13. Saretzki G, Ludwig A, von Zglinicki T, Runnebaum IB. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther 2001;8:827-34.
14. Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999;5:1164-70.
15. Kim MM, Rivera MA, Botchkina IL, Shalaby R, Thor AD, Blackburn EH. A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc Natl Acad Sci USA 2001;98:7982-7.
16. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 1998;16:3323-30.
17. Folini M, Colella G, Villa R, Lualdi S, Daidone MG, Zaffaroni N. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. J Investig Dermatol 2000;114:259-67.
18. Kanazawa Y, Ohkawa K, Ueda K, et al. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem Biophys Res Commun 1996;225:570-6.
19. Yokoyama Y, Takahashi Y, Shinohara A, et al. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res 1998;58:5406-10.
20. Tu G, Kirchmaier AL, Liggitt D, et al. Non-replicating Epstein-Barr virus-based plasmids extend gene expression and can improve gene therapy in vivo. J Biol Chem 2000;275:30408-16.
21. Kashani-Sabet M, Liu Y, Fong S, et al. Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc Natl Acad Sci USA 2002;99:3878-83.
22. Liu Y, Thor A, Shtivelman E, Cao Y, Heath T, Debs R. Systemic gene delivery expands the repertoire of effective anti-angiogenic agents. J Biol Chem 1999;274:13338-44.
23. Chen JL, Blasco MA, Greider CW. Secondary structure of vertebrate telomerase RNA. Cell 2000;100:503-14.
24. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science 1995;269:1236-41.
25. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988;334:585-91.
26. Chadeneau C, Siegel P, Harley C, Muller WJ, Bachetti S. Telomerase activity in normal and malignant murine tissues. Oncogene 1995;11:893-8.
27. Liu Y, Mounkes LC, Liggitt HD, et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 1997;15:167-73.
28. Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 1996;16:2932-9.
29. Ito I, Began G, Mohiuddin I, et al. Increased uptake of liposomal-DNA complexes by lung metastases following intravenous administration. Mol Ther 2003;3:409-18.
30. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
31. Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002;19:500-5.
32. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature 2002;418:38-9.
33. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003;21:635-7.
34. Stein CA. The experimental use of antisense oligonucleotides: a guide for the perplexed. J Clin Investig 2001;108:641-4.
35. Scherer LJ, Rossi JJ. Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 2003;21:1457-65.
36. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
37. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
38. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.